HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.

Abstract
The inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU) on the growth of both MDA-MB-435 human breast carcinoma and 9L rat gliosarcoma cells expressing the thymidine kinase (tk)-encoding gene of the Varicella zoster virus (VZV) or the Herpes simplex virus (HSV) were evaluated. In vitro, BVDU and BVaraU effectively killed both cell types expressing VZVtk, with 50% inhibitory concentration values ranging from 0.06 to 0.4 microM, whereas ganciclovir (GCV) lacked activity. On HSVtk+ cells, BVDU had high cytotoxic activity, with 50% inhibitory concentration values that were similar to those of GCV, whereas BVaraU was inactive. In vivo, BVDU applied intraperitoneally caused a 50% tumor growth inhibition in nude mice inoculated subcutaneously with VZVtk+ as well as HSVtk+ mammary tumor cells. In mice and at variance with the in vitro results, BVaraU had very little activity against the VZVtk+ mammary cells; GCV had the highest activity on the HSVtk+ cells, resulting in a 50% eradication of the tumors. With the 9L rat gliosarcoma model, the VZVtk/BVDU system completely failed to inhibit the development of VZVtk+ glioma tumors induced subcutaneously in syngeneic rats, although BVDU had a similar 45-minute half-life in both rats and mice. Factors other than degradation of the prodrug and related to the mode of action of these analogs are possibly involved in the observed discrepancies between the in vitro and in vivo results.
AuthorsC Grignet-Debrus, V Cool, N Baudson, B Degrève, J Balzarini, L De Leval, S Debrus, T Velu, C M Calberg-Bacq
JournalCancer gene therapy (Cancer Gene Ther) Vol. 7 Issue 2 Pg. 215-23 (Feb 2000) ISSN: 0929-1903 [Print] England
PMID10770629 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Antiviral Agents
  • brivudine
  • Arabinofuranosyluracil
  • sorivudine
  • Thymidine Kinase
  • Bromodeoxyuridine
Topics
  • Animals
  • Antineoplastic Agents (metabolism, toxicity)
  • Antiviral Agents (metabolism, toxicity)
  • Arabinofuranosyluracil (analogs & derivatives, toxicity)
  • Breast Neoplasms (drug therapy, pathology)
  • Bromodeoxyuridine (analogs & derivatives, metabolism, toxicity)
  • Female
  • Genetic Vectors
  • Herpesvirus 3, Human (drug effects, enzymology, genetics)
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Rats
  • Rats, Inbred F344
  • Simplexvirus (drug effects, enzymology, genetics)
  • Thymidine Kinase (biosynthesis, genetics)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: